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Abstract
The concept that abnormal protein aggregates show prion-like propagation between cells has been considered to
explain the onset and progression of many neurodegenerative diseases. Indeed, both synthetic amyloid-like fibrils
and pathogenic proteins extracted from patients’ brains induce self-templated amplification and cell-to-cell
transmission in vitro and in vivo. However, it is unclear whether exposure to exogenous prion-like proteins can
potentially cause these diseases in humans. Here, we investigated in detail the prion-like seeding activities of
several kinds of pathogenic α-synuclein (α-syn), including synthetic fibrils and detergent-insoluble fractions
extracted from brains of patients with α-synucleinopathies. Exposure to synthetic α-syn fibrils at concentrations
above 100 pg/mL caused seeded aggregation of α-syn in SH-SY5Y cells, and seeded aggregation was also observed
in C57BL/6 J mice after intracerebral inoculation of at least 0.1 μg/animal. α-Syn aggregates extracted from brains of
multiple system atrophy (MSA) patients showed higher seeding activity than those extracted from patients with
dementia with Lewy bodies (DLB), and their potency was similar to that of synthetic α-syn fibrils. We also examined
the effects of various methods that have been reported to inactivate abnormal prion proteins (PrPSc), including
autoclaving at various temperatures, exposure to sodium dodecyl sulfate (SDS), and combined treatments. The
combination of autoclaving and 1% SDS substantially reduced the seeding activities of synthetic α-syn fibrils and
α-syn aggregates extracted from MSA brains. However, single treatment with 1% SDS or generally used sterilization
conditions proved insufficient to prevent accumulation of pathological α-syn. In conclusion, α-syn aggregates
derived from MSA patients showed a potent prion-like seeding activity, which could be efficiently reduced by
combined use of SDS and autoclaving.
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Introduction
Intracellular accumulations of abnormal protein aggre-
gates are common but defining neuropathological features
of many neurodegenerative diseases. The distributions
and spreading of these pathological proteins are closely
correlated with clinical symptoms and progression [9, 49].
Recently, it has been suggested that the prion-like behav-
ior of abnormal proteins may account for the onset and
progression of neurodegenerative diseases [21, 62]. A
growing body of evidence supports the idea that template-
mediated amplification and intracerebral transmission of
abnormal proteins are the main mechanisms by which
pathological proteins spread along the neural circuits in
the brain, although the molecular mechanisms of cell-to-
cell transmission remain to be fully clarified.
α-Synucleinopathies, which include Parkinson’s disease
(PD), dementia with Lewy bodies (DLB) and multiple
system atrophy (MSA), are characterized by accumulation
of misfolded α-synuclein (α-syn) aggregates in neuronal
and/or glial cells, and various pathological phenotypes and
clinical symptoms are observed for each disease [22]. In
PD and DLB, α-syn pathologies are mainly observed in
neurons in the form of Lewy bodies (LBs) and Lewy neur-
ites (LNs) [4, 56], whereas glial cytoplasmic inclusions
(GCIs) are seen in oligodendrocytes in MSA [61]. The
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abnormal α-syn observed in brains of patients is accumu-
lated as fibrous or filamentous forms with cross-β struc-
tures [54, 55], existing in phosphorylated and partially
ubiquitinated states [18, 24]. These abnormal α-syn
species exhibit seeding activity to induce prion-like con-
version, detergent-insolubility and protease-resistance of
endogenous α-syn [38], being similar in these respects to
the infectious forms of prion protein (PrPSc) causing
Creutzfeldt-Jakob disease (CJD) and bovine spongiform
encephalopathy [45].
α-Syn is a natively unfolded protein of 140 amino acid
residues, which is localized in synaptic termini at rela-
tively high concentration [33]. Although its physiological
function has not been fully clarified, it appears to be
involved in the regulation of SNARE complex and in
dopamine production [1, 6, 12, 13]. Disease-linked
missense mutations and multiplication of the SNCA
gene encoding α-syn have been reported in familial
forms of α-synucleinopathies, indicating that structural
changes and overexpression of α-syn protein are in-
volved in the development of synucleinopathies [42].
Recombinant soluble α-syn proteins purified from
bacterial cells expressing α-syn form amyloid-like fibrils
that are morphologically and physicochemically similar
to those observed in patients’ brains in vitro, upon shak-
ing at 37 °C for a few days [14, 51]. These synthetic α-
syn fibrils can act as seeds and induce seeded aggrega-
tion of α-syn in cultured cells or primary cultured neu-
rons, as well as in rodent brains [25]. Intracerebral
inoculation of synthetic α-syn fibrils induces phosphory-
lated and ubiqutinated α-syn pathologies not only in
transgenic (Tg) mice overexpressing human α-syn, but
also in wild-type (WT) mice [31, 32, 36]. In particular,
Tg mice overexpressing mutant human α-syn develop le-
thal central nervous system (CNS) disorder after being
inoculated with fibrils [37]. It has also been shown that
brain homogenates or insoluble fractions extracted from
brains of patients with α-synucleinopathies induce α-syn
pathologies in animal brains [5, 36, 47, 63]. In addition,
recent studies have suggested that α-syn strains with
distinct conformations exist, which is a characteristic of
prions. Synthetic α-syn fibrils formed under different
physiological conditions in vitro showed distinct seeding
activities and cytotoxicities in cultured cells and rat
brains [8, 43]. Furthermore, MSA brain extracts exhibit
distinct infectivity compared to PD or control brain
extracts in human embryonic kidney (HEK) 293 cells
expressing mutant A53T α-syn fused to yellow fluores-
cent protein and in TgM83 hemizygous mice expressing
mutant A53T α-syn [46, 66].
These experimental demonstrations of prion-like
propagation show that abnormal α-syn can trigger self-
templated amplification of abnormal forms and spread
throughout the brain. On the other hand, there is no
report or evidence as yet to indicate that infection of
pathogenic α-syn between individuals can occur, or that
onset of α-synucleinopathy can occur following exposure
to contaminated environments. It is also unclear to what
extent materials contaminated with pathogenic α-syn
pose a risk of secondary infection to patients, clinicians
and researchers. These are clearly important issues, be-
cause iatrogenic transmission of PrPSc from human
tissues derived from patients with CJD (e.g. dura mater
transplants and growth hormone treatments) or from
surgical instruments contaminated with PrPSc is well
documented [11]. Therefore, we need to examine
whether iatrogenically acquired abnormal α-syn may
cause synucleinopathy or accelerate clinical symptoms.
Here, we examined this question by characterizing the
seeding activities of synthetic α-syn fibrils and abnormal
α-syn extracted from brains of patients with MSA and
DLB.
We have already established experimental models for
seeded aggregation of α-syn using SH-SY5Y cells, as well
as in vivo models in WT rodents and primates inoculated
intracerebrally with synthetic α-syn fibrils [36, 41, 53].
Our previous study showed that the size of the amyloid-
like fibrils is the key factor that determines the efficiency
of seeded aggregation and propagation in these models
[58]. In this study, we further investigated the seeding ac-
tivities of these pathogenic α-syn species, focusing on how
much pathogenic α-syn is required to seed the formation
of intracellular aggregates of transiently expressed or en-
dogenous normal α-syn beyond the capacity of mainten-
ance mechanisms, such as lysosomal, proteasomal and
autophagy-mediated protein degradation systems, to re-
move them. We also investigated whether the abnormal
α-syn aggregates derived from MSA and DLB patients’
brains show distinct prion-like properties characteristic of
each disease, compared to synthetic α-syn fibrils, in our
models.
It is also important to consider inactivation method-
ology. It has been reported that a commercially available
alkaline cleanser, a hydrogen peroxide solution contain-
ing Cu2+ ions, and 1% sodium dodecyl sulfate (SDS) are
effective for removing pathogenic α-syn adhering to
surgical materials and laboratory instruments [7, 60]. In
addition, BioHOCl effectively reduced the seeding activ-
ity of pathogenic α-syn derived from brains with Lewy-
body pathology, as determined with a real-time quaking
induced conversion (RT-QuIC) assay [26]. On the other
hand, formalin fixation of tissues containing α-syn
pathology derived from patients with synucleinopathies
and from symptomatic Tg mice had little effect on seed-
ing activity or infectivity [50, 65]. Notably, we found that
α-syn aggregates derived from MSA patients’ brains
(MSA-syn) exhibited much higher seeding activity than
those from DLB cases. Fortunately, however, MSA-syn
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and other abnormal α-syn could be efficiently reduced
by combined use of SDS and autoclaving. The present
findings, together with previous work, suggests that
safety measures to destroy pathogenic α-syn should be
mandatory in hospitals and laboratories.
Materials and methods
Expression and purification of α-syn protein
Escherichia coli BL21 (DE3) was transfected with bacterial
expression plasmid pRK172, a construct containing
human WT or mouse α-syn that lacks cysteine due to
mutagenesis of codon 136 (TAC to TAT) [34], and the
expressed protein was purified as described [39]. Protein
concentrations of α-syn were determined by reverse-phase
HPLC as described [35].
Preparation of recombinant α-syn fibrils
Purified recombinant α-syn proteins (5 mg/ml) containing
30 mM Tris-HCl (pH 7.5), 10 mM DTT and 0.1% sodium
azide were incubated for 7 days at 37 °C in a horizontal
shaker (Taitec) at 200 rpm, then ultracentrifuged at
113,000×g for 20 min at 25 °C. The pellets were washed
with saline and ultracentrifuged as before. The resulting
pellets were collected as α-syn fibrils and resuspended in
30 mM Tris-HCl (pH 7.5). The fibrils at a concentration
of 2 mg/ml were fragmented using a cup horn sonicator
(Sonifier® SFX, Branson) at 35% power for 180 s (total
240 s, 30 s on, 10 s off), then aliquoted and cryopreserved.
For electron microscopy, α-syn fibrils (0.2 μg) were
dropped on carbon-coated 300-mesh copper grids (Nissin
EM) and incubated for 3 min. After removal of surplus
material, the fibrils were negatively stained for 3 min with
a drop of 2% sodium phosphotungstate and dried.
Electron micrograph images were obtained with a JEOL
JEM-1400 electron microscope (JEOL).
Ethics statement
Postmortem brain tissues, which had been neuropatho-
logically confirmed as MSA or DLB, were obtained from
the Brain Bank for Aging Research in Tokyo Metropol-
itan Geriatric Hospital & Institute of Gerontology,
(Tokyo, Japan). The study protocol was approved by the
ethics committees of Tokyo Metropolitan Geriatric
Hospital and Tokyo Metropolitan Institute of Medical
Science. All methods were performed in accordance with
the relevant guidelines and regulations. All brain tissues
used in this study were anonymized.
All mice were housed at the Tokyo Metropolitan Insti-
tute of Medical Science (TMiMS) in a facility in compli-
ance with Guidelines for Proper Conduct of Animal
Experiments (Science Council of Japan). Experimentation
followed TMiMS Animal Care and Use Committee
approved protocol #17018 in compliance with Guidelines
for Proper Conduct of Animal Experiments (Science
Council of Japan).
Preparation of sarkosyl-insoluble fractions from patients’
brains
For each case, a brain sample (0.5 g) was homogenized
in 20 volumes (w/v) of A68 buffer (10 mM Tris-HCl
pH 7.5 containing 10% sucrose, 0.8 M NaCl, 1 mM
EGTA) and incubated for 30 min at 37 °C, after addition
of sarkosyl (final concentration: 2%). Brain homogenates
were centrifuged at 9460×g for 10 min at 25 °C, then
ultracentrifuged at 113,000×g for 20 min at 25 °C. The
pellets were washed with saline and ultracentrifuged as
before. The resulting pellets were collected as sarkosyl-
insoluble fractions of patients’ brains, resuspended in
30 mM Tris-HCl (pH 7.5) by sonication for 15 s, and
used for introduction into cultured cells or for inactiva-
tion treatments. Resuspended fractions were centrifuged
at 1000 g for 5 min. The supernatants were used for
stereotaxic inoculation.
For immunoblotting analysis, sarkosyl-insoluble frac-
tions were added to SDS-sample buffer and boiled for
3 min. The samples were separated by 12% SDS-PAGE.
Immunoblotting with mouse monoclonal antibody
PSer129 (1:1000) directed against α-syn phosphorylated
at Ser129 [18] and other anti-α-syn antibodies, including
syn131-140 (1:2000, Cosmo bio), LB509 (1:1000) and
Syn102 (1:1000) was performed as described [52]. LB509
and Syn102 were kind gifts from Dr. Takeshi Iwatsubo.
Phosphorylated tau was detected with monoclonal anti-
Tau antibody T46 (1:1000, Thermo Fisher Scientific).
Quantification of α-syn by immunoblotting
The concentrations of α-syn in sarkosyl-insoluble
fractions extracted from human brain samples were
determined by immunoblotting. The standard curve was
generated using serial dilutions of recombinant phos-
phorylated human α-syn monomer. Phosphorylated α-
syn was detected with mouse monoclonal anti-PSer129
antibody. The band intensities of immunoblots were
quantified using ImageQuant TL.
The concentrations of α-syn expressed in WT mice were
calculated by immunoblotting as below. The standard
curves were generated using recombinant mouse α-syn.
C57BL/6 mouse brains were homogenized in A68 buffer
and centrifuged at 10,000 g for 5 min. The supernatant
were collected as A68-soluble fraction and immunoblotted
with polyclonal anti-mouse α-syn antibody (1:1000, Cell
Signaling Technology).
Immunoelectron microscopy
Sarkosyl-insoluble fractions extracted from MSA and
DLB patients’ brains were dropped onto carbon-coated
nickel grids (Nissin EM). The grids were immunostained
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with an anti-phosphorylated α-syn rabbit monoclonal
antibody EP1536Y (Abcam, 1:200) and a secondary anti-
body conjugated to 5 nm gold particles (BBI Solutions,
1:50) as described [23]. Electron micrograph images
were recorded with a JEOL JEM-1400 electron micro-
scope (JEOL).
Cell culture, transfection of plasmids and introduction of
pathogenic proteins into cells
Human neuroblastoma SH-SY5Y cells were maintained at
37 °C in 5% CO2 in Dulbecco’s modified Eagle’s medium
(DMEM)/F12 medium (Sigma-Aldrich) supplemented
with 10% fetal calf serum, penicillin-streptomycin glutam-
ine (Gibco), and MEM nonessential amino acids solution
(Gibco). Cells were cultured to 40–50% confluence in
collagen-coated 6-well plates and transfected using X-
tremeGENE 9 (Roche Life Science) with pcDNA3 encod-
ing human WT α-syn (1.5 μg) according to the manufac-
turer’s instructions. After transfection of plasmids, cells
were incubated for 6–8 h, and pathogenic proteins (2 μl)
were introduced using MultiFectam (Promega) according
to the manufacturer’s instructions. Transfected cells were
incubated for 3 days.
Preparation of sarkosyl-insoluble fractions from
transfected cells and immunoblotting
Transfected SH-SY5Y cells were collected and extracted
with 1 ml of 1% sarkosyl in A68 buffer. Cell extracts
were sonicated for 15 s on ice. After incubation for
30 min at 37 °C, cell extracts were ultracentrifuged at
113,000×g for 20 min at 25 °C. The supernatants were
removed and collected as sarkosyl-soluble fractions, then
the pellets were washed with 30 mM Tris-HCl (pH 7.5)
and ultracentrifuged as before. The resulting pellets were
collected as sarkosyl-insoluble fractions, resuspended in
30 mM Tris-HCl (pH 7.5) and sonicated for 15 s.
Sarkosyl-insoluble and -soluble fractions were added to
SDS-sample buffer and boiled for 3 min. The protein
concentrations of samples were determined with a Pierce
BCA Protein Assay Kit (Thermo Fisher Scientific). Im-
munoblotting was performed with mouse monoclonal
anti-PSer129 antibody (1:1000) and polyclonal antibody
syn131–140 (1:2000, Cosmo Bio). In immunoblotting,
monoclonal anti-α-tubulin (1:1000, Sigma) was used to
obtain a loading control. All experiments were per-
formed at least three times. The band intensities of
immunoblots were quantified using ImageQuant TL.
The ID50 was calculated by the Spearman-Karber
method based on the band intensities.
Immunofluorescence microscopy
Transfection of plasmids and introduction of pathogenic
proteins were conducted as described above, using SH-
SY5Ycells grown on coverslips. After incubation for 3 days,
cells were fixed with 4% paraformaldehyde and treated
with an anti-phosphorylated α-syn rabbit monoclonal anti-
body EP1536Y (1:1000, Abcam) and the secondary anti-
body (anti-rabbit IgG-conjugated Alexa-568, Invitrogen) as
described [57]. The cells were mounted and analyzed using
a BZ-X710 fluorescence microscope (Keyence).
Mice
C57BL/6 J mice were purchased from CLEA Japan, Inc.
α-Syn inoculation into mouse brains and
immunohistochemistry
α-Syn samples (5 μl) were inoculated into striatum (A-P:
0.2 mm; M-L: − 2.0 mm; D-V: − 2.6 mm) as described
[35]. The inoculum was injected at a rate of 5 μl per min
and the needle was kept in place at the injection site for
3 min or more. At 3 months after inoculation, mice were
anesthetized with isoflurane and killed by decapitation.
Brains were fixed with 10% formalin neutral buffer
solution (Wako) and sectioned at 50 μm with a Leica
VT1200S (Leica). Immunohistochemistry with an anti-
phosphorylated α-syn rabbit monoclonal antibody
EP1536Y (1:1000, Abcam) was performed as described
[53]. α-Syn pathologies were observed and recorded with
a BZ-X710 fluorescence microscope (Keyence). Immu-
noreactivity for pS129 α-syn was quantified using images
of coronal sections from four different regions (frontal
cortex, striatum, amygdala, substantia nigra); 4–7
sections per animal for each region were used for
quantification. PS129-positive cells were counted in 20×
(striatum, amygdala and substantia nigra) or 10× (frontal
cortex) images using BZ-H3C Hybrid Cell Count
Software (Keyence).
Inactivation and protease treatments
Synthetic α-syn fibrils (2 mg/ml) and sarkosyl-insoluble
fractions extracted from MSA patients’ brains were incu-
bated in saline or in 0.1% or 1% sodium dodecyl sulfate
for 1 h at room temperature. Pathogenic α-syn in saline
or 0.1% or 1% SDS was also incubated at 100 °C for
3 min, 120 °C for 20 min or 134 °C for 20 min. Incuba-
tions at 120 °C and 134 °C were performed using an
laboratory autoclave, LSX-300 (Tomy). For protease K
treatment, inactivated synthetic α-syn fibrils were treated
with 5 μg/ml protease K at 37 °C for 30 min. The
reaction was stopped by boiling, and samples were
analyzed by immunoblotting with polyclonal antibody
syn102–116 (1:2000) directed against a synthetic peptide
(residues 102–116) (Cosmo Bio).
Statistical analysis
The DLB and MSA data presented in Fig. 3b were
analyzed using Welch’s modified t-test. All other data
were analyzed using a one-way ANOVA followed by
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Dunnett’s post hoc test. In both cases, a P value < 0.05
was regarded as statistically significant.
Results
Seeded aggregation induced by synthetic α-syn fibrils in
SH-SY5Y cells
First, we investigated the minimum amounts of patho-
genic α-syn required to induce seeded aggregation and
accumulation of phosphorylated α-syn in SH-SY5Y cells
expressing untagged human wild-type (WT) α-syn.
Serial dilutions from 10− 1 to 10− 7 of 1 mg/ml (70 μM)
synthetic human WT α-syn fibrils (Fig. 1a) were soni-
cated for 3 min and then introduced into SY5Y cells as
previously reported [41]. After 3 days, the sarkosyl-
insoluble fraction was prepared from the transfected
cells and accumulation of phospho-α-syn was analyzed
by immunoblotting with PS129 antibody (Fig. 1b). The
results of quantitation of the insoluble phosphorylated
α-syn are shown in Fig. 1c. Accumulation of phospho-α-
syn was detected in cells treated with α-syn fibrils
diluted to 10− 3, but no increase was observed in cells
treated with dilutions from 10− 4 to 10− 7. The relative
amounts of insoluble α-syn formed in cells were in-
creased concentration-dependently by addition of α-syn
fibrils at dilutions from 10− 1 to 10− 4, but the amount
was saturated at more than 10− 1 dilution (Fig. 1c). Based
on protein determination by immunoblotting, the ID50
(50% infectious dose or seeding activity) per 2 μL was
calculated to be 102.91 (± 0.51) by the Spearman-Karber
method [64]. These results show that exposure of SH-
SY5Y cells transiently expressing human α-syn to
synthetic human α-syn fibrils at a concentration of above
100 pg/mL can induce seeded aggregation of the intra-
cellular α-syn.
Characterization of insoluble α-syn extracted from brains
of patients with α-synucleinopathies
Next, we investigated the prion-like properties of α-syn
aggregates derived from postmortem brain tissues of
patients with α-synucleinopathies. To examine whether
there are structural and biochemical differences between
α-syn aggregates in DLB and MSA, we performed
immuno-electron microscopy and immunoblotting of
sarkosyl-insoluble fractions extracted from patients’
a b
c
Fig. 1 Seed-dependent α-syn aggregation induced by serial dilutions of synthetic α-syn fibrils in SH-SY5Y cells. a Electron microscopy of human
α-syn fibrils after sonication for 180 s. Negatively stained short fibrils less than 100 nm in size were observed. Scale bar, 100 nm. b Serial 10-fold
dilutions of human α-syn fibrils (2 μl) were introduced into SH-SY5Y cells transiently expressing human WT α-syn in the presence of the transfection
reagent. Immunoblot analysis of sarkosyl-insoluble fractions (ppt) and sarkosyl-soluble fractions (sup) extracted from mock-transfected cells or cells
transfected with human α-syn fibrils in the range of 2 μg (1) to 0.2 pg (10− 7) are shown. Phosphorylated α-syn was detected with anti-phosphorylated
α-syn PSer129 antibody. α-Syn was detected with anti-syn 131–140 antibody c Quantification of phosphorylated α-syn accumulated in SH-SY5Y cells
exposed to serial dilutions of synthetic human α-syn fibrils. Band intensities from the immunoblot analyses shown in b were measured. The results are
expressed as means ± SEM (n = 3).
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brains. PS129-positive α-syn fibrous structures with 5–
10 nm diameter and 0.1 to 1 μm length were observed
in both cases, as previously reported [55] (Fig. 2a). Fi-
brils derived from MSA and labeled with PS129 antibody
appeared slightly different from those derived from DLB.
A majority of the fibrils were twisted with 80–100 nm
periodicity in MSA, while thinner, straight fibrils were
observed in DLB (Fig. 2a). Fibrous structures from DLB
were subtle curvy and longer compared to those from
MSA (Fig. 2a). Immunoblot analysis of sarkosyl-
insoluble fractions extracted from DLB and MSA
patients’ brains with LB509, syn131–140 and Syn102
antibodies showed different banding patterns. All the
antibodies detected 22, 29 and 37 kDa α-syn species in
DLB, while 22 and 32 kDa α-syn species were detected
in MSA (Fig. 2b). It is reported that these bands detected
in DLB are ubiquitinated forms of α-syn [2, 24], suggest-
ing that accumulated α-syn shows distinct post-
translational patterns in DLB and MSA.
Prion-like properties in SH-SY5Y cells of α-syn aggregates
extracted from patients’ brains
To examine the seeded aggregation of α-syn in cultured
cells, we prepared sarkosyl-insoluble fractions from 3
cases of MSA (cerebellum, frontal cortex and putamen),
4 cases of DLB (frontal cortex and temporal cortex), one
case of Alzheimer’s disease (AD) and one control, and
analyzed them by immunoblotting with PS129 and anti-
tau antibody T46. PS129-positive phospho-α-syn bands
were detected in all the sarkosyl-insoluble fractions from
both MSA and DLB (Additional file 1: Figure S1A).
Pathological-tau (PHF-tau) bands at 60, 64, and 68 kDa
together with C-terminal fragments were detected in AD
and one case of DLB (Additional file 1: Figure S1A).
Pathological tau and α-syn bands were not detected in
the control case. The concentrations of phosphorylated
α-syn in these sarkosyl-insoluble fractions were calcu-
lated from a calibration curve prepared with recombin-
ant phosphorylated α-syn (Additional file 1: Figure S1B
and Additional file 2: Table S1A). MSA-2 samples
(frontal cortex and putamen) contained high concentra-
tions of α-syn (3.58 and 7.72 ng/μl, respectively), but the
other MSA and DLB samples contained lower amounts
of α-syn in the range of 1.11~ 1.94 ng/μl (Additional file 2:
Table S1A). The same amount (2 μL) of the sarkosyl-
insoluble fractions was introduced into SH-SY5Y cells
transiently expressing untagged human WT α-syn with
Multifectam (Promega), and the cells were cultured for
three days. Seeded aggregation in the cells was detected
by immunoblotting of sarkosyl-insoluble phosphorylated
α-syn. Little or no increase of phosphorylated α-syn was
detected in cells treated with α-syn aggregates derived
from DLB brains (DLB-syn from frontal and temporal cor-
texes) compared to those in cells treated with α-syn from
control and AD brains (Fig. 3a and b). On the other hand,
α-syn aggregates derived from MSA brains (MSA-syn) in-
duced a marked increase of insoluble phosphorylated α-
syn (Fig. 3a and b). Phosphorylated α-syn was not derived
from the brain samples added to the cells, since no phos-
phorylated α-syn was detected in the insoluble fraction of
SH-SY5Y cells without transient expression of α-syn after
transduction with MSA-syn (data not shown). In addition,
the accumulation of insoluble α-syn was correlated with
the formation of PS129-positive α-syn aggregates in SH-
SY5Y cells (Fig. 3c). These results are consistent with
previous reports that MSA prions induced fluorescence-
b
Fig. 2 Characterization of α-syn aggregates extracted from brains of synucleinopathy patients. a Immunoelectron microscopy of sarkosyl-
insoluble fractions extracted from DLB (left) and MSA (right) patients’ brains. Electron micrographs show fibrous structures positive for PSer129
antibody EP1536Y, that were labeled with secondary antibody conjugated to 5 nm gold particles. Scale bar, 50 nm. b Immunoblot analyses of
sarkosyl-insoluble fractions prepared from brains of synucleinopathy patients. Sarkosyl-insoluble α-syn (22, 29 and 37 kDa in DLB, and 22 and
32 kDa in MSA) were detected by LB509 (left), anti-syn 131–140 (center) and Syn 102 (right) antibodies
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labeled α-syn aggregate formation in HEK 293 cells and
earlier lethal CNS disorders in TgM83 hemizygous
mice, whereas PD prions did not show similar infect-
ivity [46, 66]. Next, we quantitated the prion-like seeding
activities of MSA-syn and DLB-syn by using serially di-
luted samples (1/2, 1/5, 10− 1, 10− 2 and 10− 3) of sarkosyl-
insoluble fractions extracted from 3 cases of MSA (cere-
bellum, frontal cortex and putamen) and 1 case of DLB
(frontal cortex). All MSA-syn exhibited high seeding activ-
ity at the concentration of 100 pg/ml, whereas DLB-syn
exhibited much lower seeding activity at the same concen-
tration (Fig. 4 and Additional file 3: Figure S2). Thus, these
results indicated that MSA-syn possesses a strain-specific
prion-like character distinct from that of DLB-syn. In
addition, no significant differences in the seeding activity
were detected among the different brain regions used in
this study. MSA-syn has high seeding activity, similar to
that of sonicated synthetic α-syn fibrils (Figs. 1c and 4).
Lewy-like α-syn pathology in WT mice inoculated with
serial dilutions of synthetic α-syn fibrils
We characterized pathogenic α-syn in WT mice by means
of the same approach as for SH-SY5Y cells. Series of di-
luted synthetic mouse α-syn fibrils were prepared and di-
lutions of 40, 10, 4, 2, 1, 10− 1 to 10− 5 μg were inoculated
into striatum in the right hemisphere of C57BL6 mice. At
3 months after inoculation, phosphorylated α-syn
pathology was examined by immunohistochemistry with
phospho-α-syn antibody PS129. In mouse brains inocu-
lated with more than 0.1 μg of synthetic mouse α-syn fi-
brils, Lewy-like pathologies were detected in striatum,
frontal cortex, amygdala, substantia nigra and entorhinal
a
b
c
Fig. 3 Prion-like properties in SH-SY5Y cells of α-syn aggregates extracted from brains of synucleinopathy patients. a Sarkosyl-insoluble fractions
extracted from patients’ brains (2 μl) were introduced into SH-SY5Y cells transiently expressing human WT α-syn. Immunoblot analysis of
sarkosyl-insoluble fractions (ppt) and sarkosyl-soluble fractions (sup) extracted from mock-transfected cells, and sarkosyl-insoluble fractions from
cerebellum, frontal cortex and putamen of 3 MSA cases, frontal cortex and temporal cortex of 4 DLB cases, control brain and an AD case.
Phosphorylated α-syn was detected with anti-phosphorylated α-syn PSer129 antibody. α-Syn was detected with anti-syn 131–140 antibody. The
α-syn concentrations of Sarkosyl-insoluble fractions derived from human brains are shown in Additional file 1: Table S1A. b Quantification of
immunoblot analyses shown in A. The results are expressed as means ± SEM (n = 3). *P < 0.05. c SH-SY5Y cells into which synthetic human α-syn
fibrils (2 μg) or sarkosyl-insoluble fractions from cerebellum of a MSA case and temporal cortex of a DLB case (2 μl) had been introduced were
fixed and immunostained with PSer129 antibody EP1536Y. Scale bar, 100 μm. Cb: cerebellum, FC: frontal cortex, Pu: putamen, TC: temporal cortex
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cortex, as previously reported [35] (Fig. 5a), whereas in-
oculation of less than 0.01 μg α-syn fibrils did not induce
α-syn pathology. To investigate the correlation between
inoculum dose and spreading of α-syn pathology, we
quantitated phosphorylated α-syn-positive cells and neur-
ites in striatum, frontal cortex, amygdala and substantia
nigra, where relatively abundant, conspicuous, broad-
spectrum pathologies were observed in our previous study
[58]. The numbers (areas) of phosphorylated α-syn-
positive nerve cells and neurites were increased in parallel
with the inoculated dose of α-syn fibrils (Fig. 5b). The in-
creases were particularly marked in striatum and frontal
cortex near the inoculation site. These results indicate that
intracerebral inoculation of at least 0.1 μg of synthetic
mouse α-syn fibrils per animal is required to induce
Lewy-like pathology in WT mouse brain, in which the
concentration of endogenous α-syn was determined to be
37.03 (± 6.71) μg/mL (Additional file 4: Figure S3).
MSA-syn induced PS129-positive α-syn pathology in
WT mice
We next investigated whether these distinct pathogenic
α-syn aggregates derived from MSA and DLB induce
different types of pathology in WT mice. MSA-syn and
DLB-syn were inoculated into the right striatum and α-
syn pathology was evaluated by immunohistochemistry
with PS129. Inoculation of MSA-syn derived from MSA-
2 (putamen), which contained the highest concentration
of phosphorylated α-syn, induced PS129-positive inclu-
sions in striatum, frontal cortex, amygdala and
substantia nigra at 3 months after inoculation (Fig. 6). α-
Syn pathologies in MSA-syn-injected mouse brains did
not resemble the GCIs-like pathology observed in MSA,
but resembled the neuronal inclusions observed in PD
and DLB. DLB-syn induced little α-syn pathology at
3 months after inoculation, and the pathology was
mostly Lewy-neurite-like, even at 9 months after inocu-
lation, as previously reported [36] (Fig. 6). No α-syn
pathology was observed in mice inoculated with the con-
trol brain sample at 3 or 9 months after inoculation (Fig.
6). These results showed that α-syn aggregates derived
from brains of patients with MSA and DLB induce dis-
tinct pathological forms of α-syn in WT mouse brains,
supporting the view that MSA-syn and DLB-syn are dis-
tinct α-syn strains.
Thus, we determined the minimum amounts of
synthetic α-syn and MSA-syn required for induction of
seeded aggregation in SH-SY5Y cells and those of
synthetic α-syn fibrils required for prion-like propaga-
tion of pathological α-syn in WT mice. In addition, we
confirmed that MSA-syn and DLB-syn show distinct
morphological and biochemical features and exhibit
strain-specific prion-like properties in these models.
Degradation of synthetic α-syn fibrils by pre-vacuum
steam sterilization and SDS
Having seen that small amounts of synthetic α-syn fibrils
and MSA-syn can cause seeded aggregation of α-syn and
induce α-syn pathology in vitro and in vivo, we next
tested whether several procedures used to inactivate
Fig. 4 Seed-dependent α-syn aggregation induced in SH-SY5Y cells by serial dilutions of insoluble fractions extracted from brains of patients with
synucleinopathies. Serial dilutions of sarkosyl-insoluble fractions prepared from cerebellum, frontal cortex and putamen of 3 MSA cases and frontal
cortex of a DLB case (2 μl) were introduced into SH-SY5Y cells transiently expressing human WT α-syn. Quantification of phosphorylated α-syn
accumulated in SH-SY5Y cells induced by serial dilutions of pathogenic α-syn derived from brain samples. Band intensities of immunoblot analysis
shown in Additional file 4: Figure S3 were measured. The results are expressed as means ± SEM (n = 3). Cb: cerebellum, FC: frontal cortex,
Pu: putamen, TC: temporal cortex
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PrPSc are also able to reduce the seeding activity of
pathogenic α-syn. Synthetic α-syn fibrils and MSA-syn
were subjected to general sterilization and inactivation
procedures for PrPSc, and the residual seeding activities
were examined using SH-SY5Y cells and WT mice. First,
we tried SDS and autoclave treatments of synthetic α-
syn fibrils. Synthetic human WT α-syn fibrils (2 mg/ml;
140 μM) were incubated for 1 h in the presence or ab-
sence of 0.1% or 1% SDS at room temperature or boiled
at 100 °C for 3 min. Autoclave treatments of α-syn fibrils
at 120 °C or 134 °C for 20 min were also conducted in
the presence or absence of 0.1% and 1% SDS. The
resulting samples were analyzed by immunoblotting with
anti-α-syn antibodies. Some degradation bands of ~
10 kDa were detected with the Syn102–116 antibody
after autoclaving synthetic α-syn fibrils (Fig. 7a), suggest-
ing that α-syn was hydrolysed by high-pressure and
high-temperature treatments. Moreover, α-syn bands
were hardly detectable with the anti-α-syn 131–140 anti-
body after autoclave treatment at 134 °C, indicating that
the α-syn C-terminal region was mostly degraded after
the higher-temperature autoclave treatment used in the
inactivation of PrPSc (Fig. 7a). The proteinase K (ProK)
resistance of these treated α-syn samples was also
b
a
Fig. 5 Dose-dependent propagation following introduction of different amounts of synthetic α-syn fibrils in non-Tg mice. a Various amounts of
mouse α-syn fibrils inoculated into WT mice dose-dependently induced α-syn pathology in frontal cortex, striatum, amygdala and substantia
nigra. α-Syn pathology in mouse brains inoculated with 40, 10, 1, and 0.1 μg of α-syn fibrils into striatum at 3 months after inoculation is shown.
The numbers of injected mice are shown in Additional file 5: Table S2A. Sections were evaluated by immunohistochemistry with PSer129
antibody EP1536Y. Scale bar, 100 μm. b Quantification of α-syn pathology in brains of mice inoculated with different amounts (40 μg to 10 pg) of
mouse α-syn fibrils into striatum. The box plots show the number of pS129-positive cells in different regions. One-way ANOVA with Dunnett’s
post hoc test was used for multiple comparisons to 10 pg, *P < 0.05; **P < 0.01. FC: frontal cortex, Str: striatum, Amy: amygdala, SN:
substantia nigra
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examined to characterize the inactivation. ProK-resistant
10 and 15 kDa bands were detected with Syn102–116 in
synthetic α-syn fibrils with or without boiling at 100 °C
for 3 min, whereas no ProK-resistant band was detected
in α-syn fibrils after autoclaving or 1% SDS treatment,
although weak bands were observed after autoclaving at
120 °C in the presence and absence of 0.1% SDS (Fig. 7a).
Seeding properties of synthetic α-syn fibrils in SH-SY5Y
cells after inactivation treatments
To test the effectiveness of the inactivation treatments,
synthetic human α-syn fibrils after these treatments were
introduced into SH-SY5Y cells and the intracellular ac-
cumulation of phosphorylated α-syn was examined by
immunoblotting with PS129. Seeding activity of α-syn fi-
brils boiled at 100 °C for 3 min was almost equal to that
of untreated fibrils (Fig. 7b and c). The single 1% SDS
treatment and the autoclaving at 120 °C in the presence
or absence of 0.1% SDS reduced the accumulation of
α-syn but 50~ 80% of the seeding activity remained
(Fig. 7b and c). On the other hand, the seeding activ-
ity was decreased by about 90% compared to that of
untreated fibrils after autoclaving at 120 °C in the
presence of 1% SDS, or 134 °C in the presence or ab-
sence of SDS (Fig. 7b, c and Table 1). In particular,
combined treatments with 1% SDS and autoclaving
resulted in almost complete abrogation of seeding ac-
tivity (Fig. 7b, c and Table 1). Notably, the seeding
activities of synthetic α-syn fibrils after various
treatments corresponded well to the amounts of
ProK-resistant bands detected with Syn102–116 and
to the degree of degradation of α-syn fibrils (Fig. 7a).
To further investigate their inactivation, synthetic α-syn
fibrils treated with 1% SDS at room temperature for 1 h,
boiling at 100 °C for 3 min and autoclaving at 134 °C in
the absence or presence of 1% SDS, then diluted serially
from 10− 1 to 10− 6, and introduced into SH-SY5Y cells.
Synthetic α-syn fibrils after boiling at 100 °C for 3 min
retained seeding activity equivalent to that of untreated
fibrils, shown in Fig. 1c (Fig. 8 and Additional file 6:
Figure S4). The single 1% SDS treatment reduced the
seeding activity to about 1/100 (Fig. 8 and Additional
file 6: Figure S4). The ID50 values per 2 μL of syn-
thetic α-syn fibrils treated with 1% SDS and with boiling
were calculated to be 102.94 (± 0.67) and 102.13 (± 0.48),
respectively. On the other hand, α-syn fibrils after auto-
claving at 134 °C in the absence or presence of 1% SDS
showed little seeding activity (Fig. 8 and Additional file 6:
Figure S4).
Inactivation of pathogenic α-syn derived from brains of
MSA patients
We also investigated whether these inactivation treat-
ments are effective for pathogenic α-syn derived from
patients with MSA. Sarkosyl-insoluble fractions ex-
tracted from 2 cases of MSA (MSA-2, putamen and
MSA-3) were treated with 1% SDS, boiling at 100 °C for
3 min, or autoclaving at 120 °C or 134 °C for 20 min in
the presence or absence of 1% SDS. Immunoblotting
with the Syn102–116 antibody showed marked degrad-
ation of insoluble α-syn after the autoclave treatments in
the presence and absence of 1% SDS, in agreement with
the results for synthetic α-syn fibrils shown in Fig. 7a
(Fig. 9a). No apparent difference in the α-syn bands was
detected between untreated MSA-syn and MSA-syn
after single treatment with 1% SDS or boiling (Fig. 9a).
When the treated MSA-syn was introduced into SH-
SY5Y cells together with the untreated samples, we
found that the seeding activity of MSA-syn from MSA-2
was dramatically reduced by about 90% after autoclaving
at 121 °C or 134 °C in the presence of 1% SDS, com-
pared to untreated MSA-syn (Fig. 9b, c and Table 1).
Single autoclave treatment at 134 °C decreased the activ-
ity by about 80% (Fig. 9b, c and Table 1). The seeding ac-
tivity was not completely lost after single 1% SDS
treatment or autoclaving at 120 °C (Fig. 9b, c and Table 1).
Boiling at 100 °C for 3 min had no effect (Fig. 9b, c and
Table 1). Interestingly, MSA-syn derived from MSA-3 ex-
hibited greater sensitivity to the inactivation treatments.
The seeding activity was partially decreased after boiling
at 100 °C for 3 min, and almost abolished after the other
treatments (Fig. 9b, c and Table 1). These results suggest
Fig. 6 α-Syn strain-specific pathology in non-Tg mice. Inoculation of
sarkosyl-insoluble fractions extracted from MSA brain (MSA-2,
putamen, 5 μl) into WT mice induced PS129-positive inclusions in
frontal cortex, striatum, amygdala and substantia nigra at 3 months
after inoculation (middle). Sarkosyl-insoluble fractions extracted from
DLB brain (5 μl) induced Lewy-neurite-like α-syn pathology at
9 months after inoculation (lower). Control brain did not induce
α-syn pathology (upper). Sections were evaluated by immunohisto-
chemistry with PSer129 antibody EP1536Y. The α-syn concentrations
of sarkosyl-insoluble fractions derived from human brains are shown
in Additional file 2: Table S1B. The numbers of injected mice are
shown in Additional file 5: Table S2C. FC: frontal cortex, Str: striatum,
Amy: amygdala, SN: substantia nigra
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ab
c
Fig. 7 Inactivation of synthetic α-syn fibrils by SDS treatment and autoclaving. a Synthetic α-syn fibrils were subjected to various inactivation
treatments and analyzed by immunoblotting with Syn 102–116 and anti-syn 131–140 antibodies (upper). Treated α-syn samples were treated with
protease K (5 μg/mL) and analyzed by immunoblotting (lower). b α-Syn fibrils were subjected to various inactivation treatments (2 μl) and
introduced into SH-SY5Y cells transiently expressing human WT α-syn. Immunoblot analysis of sarkosyl-insoluble fractions (ppt) and
sarkosyl-soluble fractions (sup) extracted from mock-transfected cells and cells transfected with α-syn monomer and fibrils, and treated with 1%
SDS for 1 h at room temperature, or boiled, or autoclaved (AC) at 120 °C with or without 0.1%, 1% SDS, or autoclaved at 134 °C with or without
0.1% or 1% SDS are shown. Phosphorylated α-syn was detected with anti-phosphorylated α-syn PSer129 antibody. α-Syn was detected with
anti-syn 131–140 antibody. c Quantification of immunoblot analysis shown in b. The results are expressed as means ± SEM (n = 3). “No treatment”
was taken as 100%. One-way ANOVA with Dunnett’s post hoc test were used for multiple comparisons to no treatment, *P < 0.05; **P < 0.01
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that some varieties of pathogenic α-syn from MSA are re-
sistant to inactivation, although differences in the concen-
tration of pathological α-syn in the fractions may also
affect the seeding activity. These results showed that the
seeding activity of synthetic α-syn fibrils could be effi-
ciently reduced by autoclaving treatment in presence of
1% SDS, and this procedure was also effective to inactivate
pathogenic α-syn derived from MSA patients.
Seeding properties of inactivated pathogenic α-syn in WT
mice
Finally, we investigated the effects of the inactivation
procedures on seeding activity in vivo. Synthetic mouse
α-syn fibrils after the inactivation treatments were inoc-
ulated into the right striatum of WT mouse brains. At
3 months after inoculation, α-syn pathology was evalu-
ated by immunohistochemistry with PS129. Synthetic α-
syn fibrils treated by boiling at 100 °C for 3 min induced
Lewy-like pathology almost equivalent to that seen after
inoculation of untreated fibrils, as had been found in the
cellular model (Fig. 10a and b). Autoclaving of synthetic
α-syn fibrils in the presence or absence of 0.1% SDS
reduced the seeding activity, and the resulting α-syn
pathologies were similar to those of mice inoculated
with 0.1 μg of untreated synthetic fibrils, shown in
Fig. 2a (Fig. 10a and b). The single autoclave treat-
ment at 134 °C was the most effective treatment to
reduce the seeding activity in mice (Fig. 10a and b).
We also performed inoculation of synthetic fibrils after
autoclaving in the presence or absence of 1% SDS, but the
effects of treatments could not be compared because the
mouse brains were partially lysed by SDS.
MSA-syn derived from MSA-2 after boiling at 100 °C
for 3 min and autoclaving at 134 °C was also inoculated
into mouse brains. At 3 months after inoculation,
PS129-positive inclusions were observed in mice injected
with boiled MSA-syn, as shown in Fig. 5, whereas no
pathology was detected in the mice injected with MSA-
syn after autoclaving at 134 °C (Fig. 11). Thus, the auto-
clave treatment at 134 °C reduced the seeding activity of
synthetic α-syn fibrils and MSA-syn sufficiently to block
induction of α-syn pathology in WT mice.
Discussion
Many experimental studies on prion-like propagation of
pathological proteins, such as α-syn, tau and TDP-43
strongly support the idea that cell-to-cell transmission of
abnormal protein aggregates is a central mechanism in
the pathogenesis and progression of many neurodegen-
erative diseases. Recent reports have also suggested that
structurally different conformations of α-syn or tau
exhibit strain-specific biochemical properties, including
differences in the efficiency of propagation and in cellu-
lar toxicities. On the other hand, these findings raise the
question of whether these pathogenic proteins can act as
prions, i.e., infectious agents that may cause the onset
and progression of neurodegenerative diseases, when
Table 1 Inactivation effects of pathogenic α-syn derived from recombinant α-syn protein and MSA patients’ brains in SH-SY5Y cells
Treatment Synthetic α-syn fibrils MSA-2 Pu MSA-3 FC
No treatment 100 (± 11.22) 100 (± 3.38) 100 (± 11.49)
1% SDS 65.5 (± 16.48) 48.6 (± 18.66) 13.8 (± 2.96)
100 °C 3 min 109.7 (± 5.00) 114.2 (± 20.45) 29.5 (± 2.07)
120 °C 20 min 45.3 (± 14.75) 75.1 (± 13.45) 17.5 (± 2.37)
120 °C 20 min/0.1% SDS 44.9 (± 4.45) not tested not tested
120 °C 20 min/1% SDS 3.3 (± 2.94) 10.5 (± 2.91) 1.7 (± 1.23)
134 °C 20 min 8.7 (± 5.31) 19.0 (± 2.13) 6.3 (± 0.93)
134 °C 20 min/0.1% SDS 11.5 (± 2.31) not tested not tested
134 °C 20 min/1% SDS 2.8 (± 2.76) 3.5 (± 0.95) 6.8 (± 0.25)
Fig. 8 Effects of inactivation treatments of synthetic α-syn fibrils on
seeding activity in SH-SY5Y cells. Serial 10-fold dilutions of human
α-syn fibrils treated with 1% SDS (red), boiling (green), autoclaving
(AC) at 134 °C (orange) or autoclaving at 134 °C with 1% SDS
(purple) were introduced into SH-SY5Y cells transiently expressing
human WT α-syn. Phosphorylated α-syn accumulated in SH-SY5Y
cells exposed to serial dilutions of synthetic human α-syn fibrils were
quantified after each treatment. Band intensities from the
immunoblot analyses shown in Additional file 6: Figure S4 were
measured. The results are expressed as means ± SEM (n = 3)
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humans are exposed to them. So far, there is no report of
transmission of these pathogenic proteins between
humans or from animals to humans, except in the case of
PrPSc. However, considering the potential consequences of
secondary infection to patients, clinicians and researchers,
it is essential to establish whether there is actually a risk of
iatrogenic or other infection. Therefore, in this study, we
examined the ability of pathogenic α-syn proteins to in-
duce prion-like seeded aggregation and to propagate in
cellular and animal models. We also investigated the
a
b
c
Fig. 9 Inactivation of pathogenic α-syn derived from brains of MSA patients. a Sarkosyl-insoluble fractions prepared from 2 MSA cases (MSA-2 Pu
and MSA-3 FC) after various inactivation treatments were analyzed by immunoblotting with anti-syn 102–116 antibody. b Sarkosyl-insoluble
fractions extracted from MSA brains after inactivation treatments (2 μl) were introduced into SH-SY5Y cells transiently expressing human WT
α-syn. Immunoblot analyses of sarkosyl-insoluble fractions (ppt) and sarkosyl-soluble fractions (sup) extracted from mock-transfected cells or cells
transfected with pathogenic α-syn derived from MSA brains and treated with 1% SDS for 1 h at room temperature, boiling, autoclaving (AC) at
120 °C with or without 1% SDS or AC at 134 °C with or without 1% SDS are shown. Phosphorylated α-syn was detected with anti-phosphorylated
α-syn PSer129 antibody. α-Syn was detected with anti-syn 131–140 antibody. c, Quantification of immunoblot analyses shown in b. The results
are expressed as means ± SEM (n = 3). “No treatment” was taken as 100%. One-way ANOVA with Dunnett’s post hoc test were used for multiple
comparisons to no treatment, *P < 0.05; **P < 0.01
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efficacy of various inactivation methods for reducing the
seeding activity of these pathogenic α-syn.
First, the seeding activities of serially diluted synthetic
α-syn fibrils and α-syn aggregates derived from brains of
synucleinopathy patients were characterized in SH-SY5Y
cells transiently expressing human WT α-syn, in terms
of formation of aggregated and phosphorylated α-syn. In
this model, synthetic α-syn fibrils caused seeded aggre-
gation of human α-syn at 7.14 pM and higher concen-
trations (Fig. 1c). The concentration of human soluble
α-syn in the cells was estimated to be 2 μM, suggesting
that the synthetic α-syn fibrils could function as seeds at
108 times lower concentration than that of normal α-
syn. Further, MSA-syn showed similar seeding activity to
the synthetic fibrils, although DLB-syn showed a lower
seeding activity (Figs. 3b and 4). The concentration of
pathogenic α-syn required for infection was similar to
that reported by Prusiner’s group, who detected seeded
aggregation by fluorescence measurement in an HEK293
cell model [66]. In the present study, the synthetic fibrils
were used after powerful sonication, which enhances
their seeding activity, as shown in our previous report.
a
b
Fig. 10 Effects of inactivation treatments of synthetic α-syn fibrils on seeding activity in non-Tg mice. a 2 mg/ml mouse α-syn fibrils were
exposed to various treatments (1% SDS for 1 h at room temperature, boiling, autoclaving (AC) at 120 °C with or without 0.1% SDS or autoclaving
at 134 °C with or without 0.1% SDS), and 5 μl aliquots of the resulting samples were inoculated into WT mice. α-Syn pathologies in frontal cortex,
striatum, amygdala and substantia nigra at 3 months after inoculation are shown. The numbers of injected mice are shown in Additional file 5:
Table S2B. Sections were evaluated by immunohistochemistry with PSer129 antibody EP1536Y. Scale bar, 100 μm. b Quantification of α-syn
pathology in mouse brains inoculated into striatum with α-syn fibrils exposed to various treatments. The box plots show the numbers of
pS129-positive cells in different regions. One-way ANOVA with Dunnett’s post hoc test were used for multiple comparisons to no treatment,
*P < 0.05; **P < 0.01. FC: frontal cortex, Str: striatum, Amy: amygdala, SN: substantia nigra
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However, MSA-syn showed high seeding activity even
without this sonication. This may indicate that there are
some structural differences between MSA-syn and the
synthetic fibrils. We also found that MSA-syn is mor-
phologically and biochemically distinct from DLB-syn
(Fig. 2). It is plausible that these differences reflect the for-
mation of the fibrils in different intracellular environments
(oligodendrocytes in MSA and neuronal cells in PD and
DLB). Further investigations will be required to under-
stand the roles of different of α-syn strains in the clinical
and pathological diversity of α-synucleinopathies.
We then used a WT mouse model to examine the
minimum infectious amount, and found that as little as
0.1 μg of synthetic α-syn fibrils could induce Lewy-like
pathology of endogenous mouse α-syn (Fig. 5). This is
quite large compared to PrPSc, and thus the infectivity of
α-syn fibrils as an environmentally acquired prion is ex-
pected to be considerably lower than that of PrPSc. The
reason for this may be that normal prion protein is
localized on the cell surface by a glycosylphosphatidyl-
inositol (GPI) anchor, but the intracellular localization of
α-syn requires that pathogens should first pass through
the cell membrane to reach their target. Lewy-like path-
ologies in synthetic fibril-injected mice increased in pro-
portion to the inoculation volume, especially around the
injection site (Fig. 5). Similar dose-dependent induction
of pathology was reported in the inoculation of synthetic
tau fibrils into PS19 Tg mice overexpressing mutant hu-
man tau (P301S), in which MC1-positive tau pathology
increased near the inoculation site when the inoculation
volumes were increased [27].
For evaluation of prion-like properties, various methods
are available, including RT-QuIC assay, prion-like propa-
gation experimental models using cultured cells, primary
cultures and animals, although they show different
sensitivities. We analyzed the prion-like seeding activity
by detecting formation of intracellular insoluble α-syn in
SH-SY5Y cells transiently expressing α-syn or in WT mice
expressing endogenous α-syn. In the cells, exposure to
synthetic α-syn fibrils at 100 pg/mL or more induced
seed-dependent aggregation. In WT mice, α-syn patholo-
gies were detectable at 3 months after intracerebral inocu-
lation of 0.1 μg synthetic mouse α-syn fibrils per animal.
The concentration of endogenous α-syn in WT (C57BL6)
mouse brain was quantitated and determined to be 37.03
(± 6.71) μg/mL. Previous studies using Tg mice, together
with our study, indicate that sensitivity to pathogenic α-
syn may vary depending upon the expression level of
intracellular α-syn, although we did not use Tg mice in the
present work. This is supported by the existence of copy
number variations (duplication and triplication) in SNCA
gene associated with early onset and rapid progression of
PD [30]. Overall, these results show that both the amount
of pathogenic protein and the concentration of intracellu-
lar normal soluble protein are key factors influencing the
onset and progression of synucleinopathies. Thus, de-
creasing the expression level of intracellular soluble α-syn
may contribute to suppression of aggregate formation,
and inhibit intracerebral propagation.
It has been experimentally investigated whether expos-
ure to pathological α-syn via peripheral routes can induce
disease onset and pathology, as is the case for PrPSc.
Several reports have shown that peripheral inoculation of
synthetic α-syn fibrils or MSA brain homogenates into
TgM83 mice can induce α-syn pathologies and lethal CNS
disorders. Inoculations into the peritoneal cavity or hind-
limb muscle resulted in disease onset with high infectivity
compared with inoculation into the tongue [3, 10, 48]. On
the other hand, α-syn pathology was not induced in WT
mice by inoculation into hindlimb muscle or oral inocula-
tion of even large amounts of synthetic α-syn fibrils [35].
These results may reflect the different expression levels of
α-syn in the host animals, as noted above. Thus, the sensi-
tivity to pathogenic proteins may depend strongly on the
type of experimental model used. Surprisingly, implant-
ation of stainless steel wires contaminated with MSA
brain homogenates into TgM83 hemizygous mice resulted
in the development of lethal CNS disorder [65]. In
addition, PrPSc adhering to stainless steel wires has been
reported to be more resistant to inactivation than PrPSc in
brain homogenates [19, 44]. These findings imply that
there may be a substantial risk of secondary infection
from surgical instruments bearing pathogenic α-syn,
such as instruments used in deep brain stimulation
(DBS) surgery to restore motor function to PD pa-
tients. Similarly, stainless steel wires contaminated
with amyloid-beta (Aβ) fraction caused amyloidosis in
TgAPP23 mice [15]. Furthermore, Jaunmuktane et al.
reported that transmission of Aβ seeds though surgi-
cal instruments might have occurred in patients who
Fig. 11 Effects of inactivation treatments of pathogenic α-syn
extracted from MSA patients’ brains on seeding activity in non-Tg
mice, α-Syn pathology in mouse brains inoculated into striatum with
sarkosyl-insoluble fractions extracted from MSA brain (MSA-2, putamen)
after boiling or autoclaving (AC) at 134 °C, at 3 months after injection.
The numbers of injected mice are shown in Additional file 5: Table S2C.
Sections were evaluated by immunohistochemistry with PSer129 anti-
body EP1536Y. Scale bar, 100 μm. FC: frontal cortex, Str: striatum, Amy:
amygdala, SN: substantia nigra
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underwent neurosurgery in childhood [28]. Thus, to
prevent iatrogenic infection, effective sterilization pro-
cedures seem mandatory.
Therefore, we next investigated the efficacy of various
commonly used inactivation methods for PrPSc for
abolishing the seeding activity of pathogenic α-syn.
Autoclave treatments at 120 °C or 134 °C in the pres-
ence of 1% SDS dramatically reduced the seeding activity
of pathogenic α-syn, including synthetic fibrils and
MSA-syn, in the cultured cell model (Figs. 7c, 9c and
Table 1). Further, pathogenic α-syn exposed to a single
autoclave treatment at 134 °C did not induce α-syn path-
ology in WT mouse brain (Fig. 10b and 11). On the
other hand, single autoclave treatment at 120 °C,
which is commonly used as a general sterilization
method, was insufficient to inactivate synthetic α-syn
fibrils or MSA-syn (Figs. 7c and 9c). The seeding
activity of pathogenic α-syn after boiling treatment
for 3 min was almost the same as that of untreated
pathogenic α-syn (Figs. 7c, 9c, 10b and 11). Similar
heat resistance has been reported for Aβ aggregates
and abnormal TDP-43 derived from ALS/frontotem-
poral lobar degeneration (FTLD) cases [15, 40].
Numerous studies on inactivation of PrPSc derived
from various biological species and strains have been
conducted, and have shown that various methods,
including strong alkaline agents, protein-denaturing
agents, proteolytic enzymes and autoclaving, are effect-
ive to abolish infectivity [20]. It has also been reported
that the level of inactivation varies depending on the
biological species and strain, but combinations of mul-
tiple treatments can reliably achieve complete inactiva-
tion [16, 59]. Thomzig and colleagues examined the
removal of Aβ, tau, and α-syn adhering to medical de-
vices by carrier assay using brain extracts of patients,
and treatments with 1 M NaOH at room temperature
for 1 h, combined treatments with 0.2% SDS or 0.3%
NaOH and autoclaving at 134 °C for 5 min, and treat-
ment with a commercial alkaline cleanser or a hydrogen
peroxide solution containing Cu2+ were reported to be
effective for removal of pathogenic α-syn [60]. On the
other hand, formalin-fixed pathogenic Aβ, tau, and α-
syn have been reported to retain high seeding activity in
vitro and in vivo [17, 29, 50]. Surprisingly, an MSA pa-
tient’s brain stored in formalin for over 20 years caused
TgM83 hemizygous mice to develop lethal CNS disorder
[65]. Thus, the suitability or unsuitability of various in-
activation procedures for prion-like proteins is becoming
clearer. Overall, PrPSc and other prion-like proteins
seem to show similar responses to inactivation proce-
dures, suggesting these pathogenic proteins have some
common structural features. Regarding the handling of
synthetic α-syn fibrils in laboratories, Bousset et al.
reported that 1% SDS and the commercial cleanser
Hellmanex can remove synthetic α-syn fibrils from sur-
faces of various materials, although they found differences
in resistance to 1% SDS among distinct α-syn strains, fi-
brils and ribbons formed under different physiological
conditions in vitro [7]. We also found differences of resist-
ance to inactivation procedures between MSA-syn prepa-
rations derived from different cases (Fig. 9c). Thus, it
remains important to manage pathogenic α-syn by using
appropriate safety cabinets to avoid human exposure.
Also, the use of a cup horn-type ultrasonicator is useful to
avoid inhalation of aerosols containing fragmented patho-
genic α-syn during sample preparation.
Conclusion
We investigated in detail the prion-like properties of
pathogenic α-syn, including synthetic α-syn fibrils,
MSA-syn and DLB-syn, using SH-SY5Y cells transiently
expressing human WT α-syn and non-Tg mice. We
found that synthetic α-syn fibrils and MSA-syn can in-
duce both prion-like amplification of abnormal α-syn in
cultured cells and spreading of phosphorylated α-syn
pathologies in mouse brain. The seeding activity of
MSA-syn is equivalent to or higher than that of syn-
thetic α-syn fibrils, though DLB-syn showed much lower
seeding activity. Various combinations of inactivation
treatments were effective to abolish the seeding activity of
these pathogenic α-syn. Our findings here provide further
evidence of the prion-like properties of pathogenic α-syn
and re-emphasize the importance of using appropriate in-
activation treatments to prevent iatrogenic and secondary
infections in the clinical and research fields.
Additional files
Additional file 1: Figure S1. Determination of protein concentration of
phosphorylated α-syn in patients’ brains. A, Sarkosyl-insoluble fractions pre-
pared from patients’ brains used in this study were analyzed by
immunoblotting with anti-phosphorylated α-syn PSer129 antibody (upper)
and anti-tau T46 antibody (lower). B, Standard curve of phosphorylated α-syn,
generated by immunoblotting of phosphorylated monomer α-syn. Concentra-
tions of phosphorylated α-syn were determined using this standard curve. Pro-
tein concentrations of sarkosyl-insoluble fractions extracted from patients’
brains are shown in Table S2. (PDF 139 kb)
Additional file 2: Table S1. α-Syn concentrations in sarkosyl-insoluble frac-
tions extracted from patients’ brains, The α-syn concentrations of sarkosyl-
insoluble fractions extracted from patients’ brains used for experiments in
the cultured cell model (A) and mouse model (B) are shown. (PDF 40 kb)
Additional file 3: Figure S2. Seeding activities of serial dilutions of
sarkosyl-insoluble fractions from brains of α-synucleinopathy patients,
Sarkosyl-insoluble fractions extracted from brains with synucleinopathy
patients were diluted and introduced into SH-SY5Y cells transiently ex-
pressing human α-syn. Immunoblot analyses of sarkosyl-insoluble frac-
tions (ppt) and sarkosyl-soluble fractions (sup) extracted from cells
transfected with serial dilutions of MSA-1(Cb), MSA-2 (FC), MSA-2 (Pu),
MSA-3 (FC) and DLB-4 (FC) are shown. Phosphorylated α-syn was de-
tected with anti-phosphorylated α-syn PSer129 antibody. α-Syn was de-
tected with anti-syn 131–140 antibody. Cb: cerebellum, FC: frontal cortex,
Pu: putamen. (PDF 283 kb)
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Additional file 4: Figure S3. Determination of protein concentration of
α-syn in C57BL/6 mouse brain, Standard curve of mouse α-syn was gen-
erated by immunoblotting of serial dilutions of recombinant mouse α-
syn protein. Protein concentrations of endogenous α-syn in mouse brains
were determined by interpolation on a standard curve. A68 buffer-
soluble fractions were extracted from C57BL/6 mouse brains (n = 3).
Bands of recombinant proteins and A68 buffer-soluble fractions were de-
tected with anti-mouse α-syn antibody. (PDF 78 kb)
Additional file 5: Table S2. Numbers of mice used in experiments.
(PDF 52 kb)
Additional file 6: Figure S4. Seeding activities of serial dilutions of
treated synthetic α-syn fibrils in SH-SY5Y cells, Serial dilutions of synthetic
α-syn fibrils exposed to various inactivation treatments were introduced
into SH-SY5Y cells. Immunoblot analysis of sarkosyl-insoluble fractions
(ppt) and sarkosyl-soluble fractions (sup) extracted from cells transfected
with serial dilutions of synthetic α-syn fibrils treated with 1% SDS for 1 h
at room temperature, boiling, or autoclaving at 134 °C with or without
1% SDS are shown. Phosphorylated α-syn was detected with anti-
phosphorylated α-syn PSer129 antibody. α-Syn was detected with anti-
syn 131–140 antibody. (PDF 248 kb)
Acknowledgments
We are grateful to the patients and their families for making brains available
for research. We thank Dr. Tetsuyuki Kitamoto and Dr. Shiro Mohri for useful
comments on PrP prions. We also thank Dr. Masami Masuda-Suzukake for
providing phosphorylated α-syn and Dr. Takashi Nonaka for helpful
comments. This work was supported by Ministry of Education, Culture,
Sports, Science, and Technology Grants-in-Aid for Scientific Research
(KAKENHI) Grants JP26117005 (to M.H.), Japan Society for the Promotion of
Science Grants-in-Aid for Scientific Research (KAKENHI) Grant JP23228004
(to M.H.), and a grant-in-aid for research on Brain Mapping by Integrated
Neurotechnologies for Disease Studies (Brain/MINDS) from the Japan Agency
for Medical Research and Development (AMED) JP14533254 (to M.H.).
Authors’ contributions
MH and AT designed the research and wrote the manuscript. AT performed
most of the experiments. TA and SM collected patients’ brain samples and
performed neuropathological diagnosis. SH, AT and MH analyzed the data.
All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Department of Dementia and Higher Brain Function, Tokyo Metropolitan
Institute of Medical Science, 2-1-6 Kamikitazawa, Setagaya-ku, Tokyo
156-8506, Japan. 2Department of Biological Science, Tokyo Metropolitan
University, Minami-osawa, Hachioji, Tokyo 192-0397, Japan. 3Department of
Neuropsychiatry, Division of Clinical Medicine, Faculty of Medicine, University
of Tsukuba, 1-1-1, Tennodai, Tsukuba, Ibaraki 305-8576, Japan. 4Department
of Neuropathology, Tokyo Metropolitan Geriatric Hospital and Institute of
Gerontology, 35-2 Sakaecho, Itabashi-ku, Tokyo 173-0015, Japan.
Received: 6 April 2018 Accepted: 6 April 2018
References
1. Abeliovich A, Schmitz Y, Farinas I, Choi-Lundberg D, Ho WH, Castillo PE et al
(2000) Mice lacking alpha-synuclein display functional deficits in the
nigrostriatal dopamine system. Neuron 25:239–252
2. Anderson JP, Walker DE, Goldstein JM, de Laat R, Banducci K, Caccavello RJ
et al (2006) Phosphorylation of Ser-129 is the dominant pathological
modification of alpha-synuclein in familial and sporadic Lewy body disease.
J Biol Chem 281:29739–29752
3. Ayers JI, Brooks MM, Rutherford NJ, Howard JK, Sorrentino ZA, Riffe CJ et al
(2017) Robust central nervous system pathology in transgenic mice
following peripheral injection of alpha-Synuclein fibrils. J Virol 91
4. Baba M, Nakajo S, Tu PH, Tomita T, Nakaya K, Lee VM et al (1998)
Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's
disease and dementia with Lewy bodies. Am J Pathol 152:879–884
5. Bernis ME, Babila JT, Breid S, Wusten KA, Wullner U, Tamguney G (2015)
Prion-like propagation of human brain-derived alpha-synuclein in transgenic
mice expressing human wild-type alpha-synuclein. Acta Neuropathol
Commun 3:75
6. Bonini NM, Giasson BI (2005) Snaring the function of alpha-synuclein.
Cell 123:359–361
7. Bousset L, Brundin P, Bockmann A, Meier B, Melki R (2016) An efficient
procedure for removal and inactivation of alpha-Synuclein assemblies from
laboratory materials. J Parkinsons Dis 6:143–151
8. Bousset L, Pieri L, Ruiz-Arlandis G, Gath J, Jensen PH, Habenstein B et al
(2013) Structural and functional characterization of two alpha-synuclein
strains. Nat Commun 4:2575
9. Braak H, Del Tredici K (2016) Potential pathways of abnormal tau and alpha-
Synuclein dissemination in sporadic Alzheimer's and Parkinson's diseases. Cold
Spring Harb Perspect Biol 8. https://doi.org/10.1101/cshperspect.a023630
10. Breid S, Bernis ME, Babila JT, Garza MC, Wille H, Tamguney G (2016)
Neuroinvasion of alpha-Synuclein Prionoids after intraperitoneal and
Intraglossal inoculation. J Virol 90:9182–9193
11. Brown P, Brandel JP, Sato T, Nakamura Y, MacKenzie J, Will RG et al (2012)
Iatrogenic Creutzfeldt-Jakob disease, final assessment. Emerg Infect
Dis 18:901–907
12. Burre J, Sharma M, Tsetsenis T, Buchman V, Etherton MR, Sudhof TC (2010)
Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro.
Science 329:1663–1667
13. Chandra S, Fornai F, Kwon HB, Yazdani U, Atasoy D, Liu X et al (2004)
Double-knockout mice for alpha- and beta-synucleins: effect on synaptic
functions. Proc Natl Acad Sci U S A 101:14966–14971
14. Crowther RA, Jakes R, Spillantini MG, Goedert M (1998) Synthetic
filaments assembled from C-terminally truncated alpha-synuclein.
FEBS Lett 436:309–312
15. Eisele YS, Bolmont T, Heikenwalder M, Langer F, Jacobson LH, Yan ZX et al
(2009) Induction of cerebral beta-amyloidosis: intracerebral versus systemic
Abeta inoculation. Proc Natl Acad Sci U S A 106:12926–12931
16. Fichet G, Comoy E, Duval C, Antloga K, Dehen C, Charbonnier A et al (2004)
Novel methods for disinfection of prion-contaminated medical devices.
Lancet 364:521–526
17. Fritschi SK, Langer F, Kaeser SA, Maia LF, Portelius E, Pinotsi D et al (2014)
Highly potent soluble amyloid-beta seeds in human Alzheimer brain but
not cerebrospinal fluid. Brain 137:2909–2915
18. Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg MS
et al (2002) Alpha-Synuclein is phosphorylated in synucleinopathy lesions.
Nat Cell Biol 4:160–164
19. Giles K, Glidden DV, Beckwith R, Seoanes R, Peretz D, DeArmond SJ et al
(2008) Resistance of bovine spongiform encephalopathy (BSE) prions to
inactivation. PLoS Pathog 4:e1000206
20. Giles K, Woerman AL, Berry DB, Prusiner SB (2017) Bioassays and inactivation
of prions. Cold Spring Harb Perspect Biol 9. https://doi.org/10.1101/
cshperspect.a023499
21. Goedert M (2015) NEURODEGENERATION. Alzheimer's and Parkinson's
diseases: the prion concept in relation to assembled Abeta, tau, and
alpha-synuclein. Science 349:1255555
22. Goedert M, Jakes R, Spillantini MG (2017) The Synucleinopathies: twenty
years on. J Parkinsons Dis 7:S53–S71
23. Hasegawa M, Arai T, Nonaka T, Kametani F, Yoshida M, Hashizume Y et al
(2008) Phosphorylated TDP-43 in frontotemporal lobar degeneration and
amyotrophic lateral sclerosis. Ann Neurol 64:60–70
24. Hasegawa M, Fujiwara H, Nonaka T, Wakabayashi K, Takahashi H, Lee VM
et al (2002) Phosphorylated alpha-synuclein is ubiquitinated in alpha-
synucleinopathy lesions. J Biol Chem 277:49071–49076
25. Hasegawa M, Nonaka T, Masuda-Suzukake M (2016) Alpha-Synuclein:
experimental pathology. Cold Spring Harb Perspect Med 6. https://doi.org/
10.1101/cshperspect.a024273
26. Hughson AG, Race B, Kraus A, Sangare LR, Robins L, Groveman BR et al
(2016) Inactivation of prions and amyloid seeds with Hypochlorous acid.
PLoS Pathog 12:e1005914
Tarutani et al. Acta Neuropathologica Communications  (2018) 6:29 Page 17 of 18
27. Iba M, Guo JL, McBride JD, Zhang B, Trojanowski JQ, Lee VM (2013) Synthetic
tau fibrils mediate transmission of neurofibrillary tangles in a transgenic mouse
model of Alzheimer's-like tauopathy. J Neurosci 33:1024–1037
28. Jaunmuktane Z, Quaegebeur A, Taipa R, Viana-Baptista M, Barbosa R, Koriath
C et al (2018) Evidence of amyloid-beta cerebral amyloid angiopathy
transmission through neurosurgery. In: Acta Neuropathol
29. Kaufman SK, Thomas TL, Del Tredici K, Braak H, Diamond MI (2017)
Characterization of tau prion seeding activity and strains from
formaldehyde-fixed tissue. Acta Neuropathol Commun 5:41
30. Konno T, Ross OA, Puschmann A, Dickson DW, Wszolek ZK (2016)
Autosomal dominant Parkinson's disease caused by SNCA duplications.
Parkinsonism Relat Disord 22(Suppl 1):S1–S6
31. Luk KC, Kehm V, Carroll J, Zhang B, O'Brien P, Trojanowski JQ et al (2012)
Pathological alpha-synuclein transmission initiates Parkinson-like
neurodegeneration in nontransgenic mice. Science 338:949–953
32. Luk KC, Kehm VM, Zhang B, O'Brien P, Trojanowski JQ, Lee VM (2012)
Intracerebral inoculation of pathological alpha-synuclein initiates a rapidly
progressive neurodegenerative alpha-synucleinopathy in mice.
J Exp Med 209:975–986
33. Maroteaux L, Campanelli JT, Scheller RH (1988) Synuclein: a neuron-specific
protein localized to the nucleus and presynaptic nerve terminal.
J Neurosci 8:2804–2815
34. Masuda M, Dohmae N, Nonaka T, Oikawa T, Hisanaga S, Goedert M et al
(2006) Cysteine misincorporation in bacterially expressed human
alpha-synuclein. FEBS Lett 580:1775–1779
35. Masuda-Suzukake M, Nonaka T, Hosokawa M, Kubo M, Shimozawa A,
Akiyama H et al (2014) Pathological alpha-synuclein propagates through
neural networks. Acta Neuropathol Commun 2:88
36. Masuda-Suzukake M, Nonaka T, Hosokawa M, Oikawa T, Arai T, Akiyama H et
al (2013) Prion-like spreading of pathological alpha-synuclein in brain.
Brain 136:1128–1138
37. Mougenot AL, Nicot S, Bencsik A, Morignat E, Verchere J, Lakhdar L et al
(2012) Prion-like acceleration of a synucleinopathy in a transgenic mouse
model. Neurobiol Aging 33:2225–2228
38. Neumann M, Kahle PJ, Giasson BI, Ozmen L, Borroni E, Spooren W et al
(2002) Misfolded proteinase K-resistant hyperphosphorylated alpha-
synuclein in aged transgenic mice with locomotor deterioration and in
human alpha-synucleinopathies. J Clin Invest 110:1429–1439
39. Nonaka T, Iwatsubo T, Hasegawa M (2005) Ubiquitination of alpha-
synuclein. Biochemistry 44:361–368
40. Nonaka T, Masuda-Suzukake M, Arai T, Hasegawa Y, Akatsu H, Obi T et al
(2013) Prion-like properties of pathological TDP-43 aggregates from
diseased brains. Cell Rep 4:124–134
41. Nonaka T, Watanabe ST, Iwatsubo T, Hasegawa M (2010) Seeded
aggregation and toxicity of {alpha}-synuclein and tau: cellular models of
neurodegenerative diseases. J Biol Chem 285:34885–34898
42. Nussbaum RL (2017) Genetics of Synucleinopathies. Cold Spring Harb
Perspect Med. https://doi.org/10.1101/cshperspect.a024109
43. Peelaerts W, Bousset L, Van der Perren A, Moskalyuk A, Pulizzi R, Giugliano
M et al (2015) Alpha-Synuclein strains cause distinct synucleinopathies after
local and systemic administration. Nature 522:340–344
44. Peretz D, Supattapone S, Giles K, Vergara J, Freyman Y, Lessard P et al (2006)
Inactivation of prions by acidic sodium dodecyl sulfate. J Virol 80:322–331
45. Prusiner SB (1998) Prions. Proc Natl Acad Sci U S A 95:13363–13383
46. Prusiner SB, Woerman AL, Mordes DA, Watts JC, Rampersaud R, Berry DB
et al (2015) Evidence for alpha-synuclein prions causing multiple system
atrophy in humans with parkinsonism. Proc Natl Acad Sci U S A
112:E5308–E5317
47. Recasens A, Dehay B, Bove J, Carballo-Carbajal I, Dovero S, Perez-Villalba A
et al (2014) Lewy body extracts from Parkinson disease brains trigger
alpha-synuclein pathology and neurodegeneration in mice and monkeys.
Ann Neurol 75:351–362
48. Sacino AN, Brooks M, Thomas MA, McKinney AB, Lee S, Regenhardt RW et al
(2014) Intramuscular injection of alpha-synuclein induces CNS alpha-
synuclein pathology and a rapid-onset motor phenotype in transgenic
mice. Proc Natl Acad Sci U S A 111:10732–10737
49. Saito Y, Kawashima A, Ruberu NN, Fujiwara H, Koyama S, Sawabe M et al
(2003) Accumulation of phosphorylated alpha-synuclein in aging human
brain. J Neuropathol Exp Neurol 62:644–654
50. Schweighauser M, Bacioglu M, Fritschi SK, Shimshek DR, Kahle PJ, Eisele YS
et al (2015) Formaldehyde-fixed brain tissue from spontaneously ill alpha-
synuclein transgenic mice induces fatal alpha-synucleinopathy in transgenic
hosts. Acta Neuropathol 129:157–159
51. Serpell LC, Berriman J, Jakes R, Goedert M, Crowther RA (2000) Fiber
diffraction of synthetic alpha-synuclein filaments shows amyloid-like
cross-beta conformation. Proc Natl Acad Sci U S A 97:4897–4902
52. Shimonaka S, Nonaka T, Suzuki G, Hisanaga S, Hasegawa M (2016)
Templated aggregation of TAR DNA-binding protein of 43 kDa (TDP-43) by
seeding with TDP-43 peptide fibrils. J Biol Chem 291:8896–8907
53. Shimozawa A, Ono M, Takahara D, Tarutani A, Imura S, Masuda-Suzukake M
et al (2017) Propagation of pathological alpha-synuclein in marmoset brain.
Acta Neuropathol Commun 5:12
54. Spillantini MG, Crowther RA, Jakes R, Cairns NJ, Lantos PL, Goedert M (1998)
Filamentous alpha-synuclein inclusions link multiple system atrophy with
Parkinson's disease and dementia with Lewy bodies. Neurosci Lett
251:205–208
55. Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M (1998) Alpha-
Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease
and dementia with lewy bodies. Proc Natl Acad Sci U S A 95:6469–6473
56. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M
(1997) Alpha-synuclein in Lewy bodies. Nature 388:839–840
57. Takahashi M, Miyata H, Kametani F, Nonaka T, Akiyama H, Hisanaga S et al
(2015) Extracellular association of APP and tau fibrils induces intracellular
aggregate formation of tau. Acta Neuropathol 129:895–907
58. Tarutani A, Suzuki G, Shimozawa A, Nonaka T, Akiyama H, Hisanaga S et al
(2016) The effect of fragmented pathogenic alpha-Synuclein seeds on
prion-like propagation. J Biol Chem 291:18675–18688
59. Tateishi J, Tashima T, Kitamoto T (1991) Practical methods for chemical
inactivation of Creutzfeldt-Jakob disease pathogen. Microbiol Immunol
35:163–166
60. Thomzig A, Wagenfuhr K, Daus ML, Joncic M, Schulz-Schaeffer WJ,
Thanheiser M et al (2014) Decontamination of medical devices from
pathological amyloid-beta-, tau- and alpha-synuclein aggregates.
Acta Neuropathol Commun 2:151
61. Wakabayashi K, Yoshimoto M, Tsuji S, Takahashi H (1998) Alpha-synuclein
immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy.
Neurosci Lett 249:180–182
62. Walker LC, Jucker M (2015) Neurodegenerative diseases: expanding the
prion concept. Annu Rev Neurosci 38:87–103
63. Watts JC, Giles K, Oehler A, Middleton L, Dexter DT, Gentleman SM et al
(2013) Transmission of multiple system atrophy prions to transgenic mice.
Proc Natl Acad Sci U S A 110:19555–19560
64. Wilham JM, Orru CD, Bessen RA, Atarashi R, Sano K, Race B et al (2010)
Rapid end-point quantitation of prion seeding activity with sensitivity
comparable to bioassays. PLoS Pathog 6:e1001217
65. Woerman AL, Kazmi SA, Patel S, Freyman Y, Oehler A, Aoyagi A et al (2017)
MSA prions exhibit remarkable stability and resistance to inactivation.
In: Acta Neuropathol
66. Woerman AL, Stohr J, Aoyagi A, Rampersaud R, Krejciova Z, Watts JC et al
(2015) Propagation of prions causing synucleinopathies in cultured cells.
Proc Natl Acad Sci U S A 112:E4949–E4958
Tarutani et al. Acta Neuropathologica Communications  (2018) 6:29 Page 18 of 18
